6Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease [J]. Parkinsonism Relat Disord, 2001, 8(2):101～108
7Katzenschlager R, lees AJ. Treatment of Parkinson's disease: levodopa as the first choice[J]. J Neurol,2002,249(2): Ⅱ 19～24
8Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-indnced motor complications in Parkinson's disease: Implication for the early use of COMT inhibitors[J]. Neurology, 2000, 55(11):72～77
9Parkinson study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease [ J ]. Arch Neurol, 2001,58 (10): 1 660～ 1 668
10Moosmann B, Skutella T, Beyer K, et al. Protective activity of aromatic amines and imines against oxidative nerve cell death [J]. Biol Chem, 2001,38(11):1 601～1 612
5Paritosh R D. The synthesis and complete H-I and C-13 NMR spectral assignment of 2,2,4,4,6,6-hexanitroadamantane and its precursor nitroketones by 2D NMR spectroscopy [ J]. Tetrahed- ton, 1992, 48.. 5839-5846.
6LIAN P, LAI W P, LI Y N, et al. Theoretical studies on the vibra- tional spectra, detonation properties, and stabilities of polynitro- adamantanes~ J], Asian Journal of Chemistry, 2015, 27 ( 1 ) : 117-119.
